Format

Send to

Choose Destination
Br J Cancer. 2014 Mar 4;110(5):1163-8. doi: 10.1038/bjc.2014.18. Epub 2014 Jan 28.

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).

Author information

1
Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2-E2, Yamadaoka, Suita 565-0871, Japan.
2
Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 3-3-1, Nakamichi, Osaka 537-8511, Japan.
3
Department of Upper Gastroenterology, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya 663-8501, Japan.
4
Department of Gastroenterological Oncology, Hyogo Cancer Center, 13-70, Kitaoji-cho, Akashi 673-8558, Japan.
5
Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2, Ohnohigashi, Osakasayama 589-8511, Japan.
6
Deparment of Medical Oncology, Keiyukai Sapporo Hospital, 1-1-14, Hondori, Sapporo 003-0027, Japan.
7
Deparment of Surgery, Sakai Municipal Hospital, 1-1-1, Yasui-cho, Sakai 590-0064, Japan.
8
Deparment of Medical Oncology, Osaki Citizen Hospital, 2-3-10, Furukawasenjujicho, Osaki 989-6183, Japan.
9
Deparment of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Osaka 565-0871, Japan.
10
Graduate School of Medicine and Engineering, University of Yamanashi, 4-4-37, Takeda, Kofu 400-8510, Japan.
11
Deparment of Cancer Center, Hokkaido University Hospital, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan.
12
Deparment of Surgery, Kaizuka City Hospital, 3-10-20, Hori, Kaizuka 597-0015, Japan.
13
Deparment of Surgery, Kinki University Faculty of Medicine, 377-2, Ohnohigashi, Osakasayama 589-8511, Japan.

Abstract

BACKGROUND:

S-1, an oral fluoropyrimidine, plus cisplatin (SP) is a standard regimen for advanced gastric cancer (AGC) in East Asia. To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP in patients with human epidermal growth factor receptor type 2 (HER2)-positive AGC.

METHODS:

Patients with HER2-positive AGC received S-1 (80-120 mg per day) orally on days 1-14, cisplatin (60 mg m(-2)) intravenously on day 1, and trastuzumab (course 1, 8 mg kg(-1); course 2 onward, 6 mg kg(-1)) intravenously on day 1 of a 21-day cycle. The primary end point was response rate (RR); secondary end points included overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), and adverse events.

RESULTS:

A total of 56 patients were enrolled. In the full analysis set of 53 patients, the confirmed RR was 68% (95% confidence interval (CI)=54-80%), and the disease control rate was 94% (95% CI=84-99%). Median OS, PFS, and TTF were estimated as 16.0, 7.8, and 5.7 months, respectively. Major grade 3 or 4 adverse events included neutropaenia (36%), anorexia (23%), and anaemia (15%).

CONCLUSIONS:

Trastuzumab in combination with SP showed promising antitumour activity and manageable toxic effects in patients with HER2-positive AGC.

PMID:
24473399
PMCID:
PMC3950868
DOI:
10.1038/bjc.2014.18
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center